LLY vs. MSFT: Eli Lilly vs. Microsoft Stock Comparison
How do Eli Lilly (LLY) and Microsoft (MSFT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Eli Lilly (LLY) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas Microsoft (MSFT) belongs to Information Technology (Software & Services) — their GICS classifications point to very different parts of the market.
| Profile Item | LLY | MSFT |
|---|---|---|
| Name | Eli Lilly and Company | Microsoft Corporation |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Information Technology |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Software & Services |
| GICS Industry | Pharmaceuticals | Software |
| GICS Sub-Industry | Pharmaceuticals | Systems Software |
| Market Capitalization | 1,057.35 billion USD | 3,712.70 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | June 1, 1972 | March 13, 1986 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | LLY | MSFT |
|---|---|---|
| Total Return (1Y) | 86.33% | -3.24% |
| Total Return (3Y, Annualized) | 38.69% | 15.74% |
| Total Return (5Y, Annualized) | 36.38% | 12.47% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | LLY | MSFT |
|---|---|---|
| Volatility (1Y, Annualized) | 35.74% | 32.09% |
| Beta (5Y) | 0.50 | 1.11 |
| Max Drawdown (5Y) | -34.48% | -37.15% |
| Avg. Volume (3M) | 3.06M | 41.13M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | LLY | MSFT |
|---|---|---|
| Sharpe Ratio (1Y) | 2.30 | -0.23 |
| Sortino Ratio (1Y) | 4.03 | -0.35 |
Profitability
ROE (TTM)
Both Eli Lilly (LLY) at 102.29% and Microsoft (MSFT) at 34.04% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
102.29%
- LLY
- 102.29%
- Max
- 102.29%
- Q3
- 2.88%
- Median
- -33.17%
- Q1
- -64.41%
- Min
- -157.61%
MSFT
Software & Services industry group
34.04%
- Max
- 62.95%
- MSFT
- 34.04%
- Q3
- 17.89%
- Median
- 5.58%
- Q1
- -13.18%
- Min
- -54.94%
Net Margin (TTM)
Eli Lilly (LLY) at 33.53% keeps the most of each sales dollar — above its industry’s net margin range — and Microsoft (MSFT) at 40.31% also retains a top-quartile share.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.53%
- LLY
- 33.53%
- Max
- 11.21%
- Q3
- 2.65%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -13.58%
MSFT
Software & Services industry group
40.31%
- Max
- 41.99%
- MSFT
- 40.31%
- Q3
- 14.87%
- Median
- 4.36%
- Q1
- -4.64%
- Min
- -30.39%
Operating Margin (TTM)
Both Eli Lilly (LLY) at 54.22% and Microsoft (MSFT) at 45.11% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
54.22%
- Max
- 94.41%
- LLY
- 54.22%
- Q3
- 8.92%
- Median
- 0.00%
- Q1
- -119.39%
- Min
- -309.54%
MSFT
Software & Services industry group
45.11%
- Max
- 47.12%
- MSFT
- 45.11%
- Q3
- 15.75%
- Median
- 4.88%
- Q1
- -7.54%
- Min
- -38.00%
Profitability Metrics
| Metric | LLY | MSFT |
|---|---|---|
| ROE (TTM) | 102.29% | 34.04% |
| ROA (TTM) | 20.36% | 14.09% |
| Net Margin (TTM) | 33.53% | 40.31% |
| Operating Margin (TTM) | 54.22% | 45.11% |
| Gross Margin (TTM) | 83.40% | 67.94% |
Growth
Revenue Growth
Both Eli Lilly (LLY) at 44.70% and Microsoft (MSFT) at 17.79% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Eli Lilly (LLY) at 95.99% sits in the top EPS growth quartile, while Microsoft (MSFT) at 31.60% is closer to the peer norm — faster per-share earnings growth for LLY.
Growth Metrics
| Metric | LLY | MSFT |
|---|---|---|
| Revenue Growth (YoY) | 44.70% | 17.79% |
| Revenue Growth (3Y CAGR) | 31.69% | 16.12% |
| EPS Growth (YoY) | 95.99% | 31.60% |
| EPS Growth (3Y CAGR) | 51.71% | 22.86% |
Financial Strength
Current Ratio (MRQ)
Microsoft (MSFT) at 1.23 keeps current ratio within its industry’s typical mid-range, while Eli Lilly (LLY) at 1.36 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for LLY.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.36
- Max
- 26.16
- Q3
- 12.25
- Median
- 5.88
- Q1
- 2.81
- LLY
- 1.36
- Min
- 0.55
MSFT
Software & Services industry group
1.23
- Max
- 5.55
- Q3
- 2.88
- Median
- 1.68
- MSFT
- 1.23
- Q1
- 1.03
- Min
- 0.03
Debt / Equity (MRQ)
Microsoft (MSFT) at 0.29 carries an industry-typical debt-to-equity mix, while Eli Lilly (LLY) at 1.62 uses more debt funding than most peers.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.62
- Max
- 1.64
- LLY
- 1.62
- Q3
- 0.68
- Median
- 0.16
- Q1
- 0.02
- Min
- 0.00
MSFT
Software & Services industry group
0.29
- Max
- 2.62
- Q3
- 1.15
- Median
- 0.33
- MSFT
- 0.29
- Q1
- 0.06
- Min
- 0.00
Financial Strength Metrics
| Metric | LLY | MSFT |
|---|---|---|
| Current Ratio (MRQ) | 1.36 | 1.23 |
| Debt / Equity (MRQ) | 1.62 | 0.29 |
| Net Debt / EBITDA | 1.10 | 0.27 |
Dividends
Dividend Yield (TTM)
Both Eli Lilly (LLY) at 0.54% and Microsoft (MSFT) at 0.73% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.54%
- LLY
- 0.54%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MSFT
Software & Services industry group
0.73%
- MSFT
- 0.73%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Both Eli Lilly (LLY) at 21.69% and Microsoft (MSFT) at 19.83% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.69%
- LLY
- 21.69%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MSFT
Software & Services industry group
19.83%
- MSFT
- 19.83%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | LLY | MSFT |
|---|---|---|
| Dividend Yield (TTM) | 0.54% | 0.73% |
| Dividend Payout Ratio (TTM) | 21.69% | 19.83% |
Valuation
P/E Ratio (TTM)
Both Eli Lilly (LLY) at 40.00 and Microsoft (MSFT) at 27.87 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.00
- Max
- 84.14
- Q3
- 43.16
- LLY
- 40.00
- Median
- 28.60
- Q1
- 15.80
- Min
- 2.32
MSFT
Software & Services industry group
27.87
- Max
- 133.34
- Q3
- 65.90
- Median
- 34.61
- MSFT
- 27.87
- Q1
- 17.12
- Min
- 0.37
P/S Ratio (TTM)
Eli Lilly (LLY) at 13.27 is priced about in line with its industry on P/S ratio, while Microsoft (MSFT) at 11.19 sits in the pricier quartile — MSFT costs more per dollar of sales.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.27
- Max
- 70.39
- Q3
- 30.57
- LLY
- 13.27
- Median
- 7.62
- Q1
- 3.50
- Min
- 0.01
MSFT
Software & Services industry group
11.19
- Max
- 19.74
- MSFT
- 11.19
- Q3
- 9.68
- Median
- 4.31
- Q1
- 2.31
- Min
- 0.02
P/B Ratio (MRQ)
Microsoft (MSFT) at 8.39 sits near its industry’s typical P/B ratio, while Eli Lilly (LLY) at 33.96 prices above its benchmark range — LLY looks rich relative to book.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.96
- LLY
- 33.96
- Max
- 17.22
- Q3
- 8.05
- Median
- 3.87
- Q1
- 1.75
- Min
- -7.69
MSFT
Software & Services industry group
8.39
- Max
- 19.84
- Q3
- 9.14
- MSFT
- 8.39
- Median
- 4.33
- Q1
- 2.00
- Min
- -8.65
Valuation Metrics
| Metric | LLY | MSFT |
|---|---|---|
| P/E Ratio (TTM) | 40.00 | 27.87 |
| P/S Ratio (TTM) | 13.27 | 11.19 |
| P/B Ratio (MRQ) | 33.96 | 8.39 |
| Free Cash Flow Yield (TTM) | 1.05% | 0.45% |